NASDAQ:RARX - Ra Pharmaceuticals Stock Price, Forecast & News

Ra Pharmaceuticals trades on the NASDAQ under the ticker symbol "RARX."

Ra Pharmaceuticals Inc (NASDAQ:RARX) announced its earnings results on Thursday, November, 7th. The company reported ($0.55) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.50) by $0.05. The business earned $3 million during the quarter. View Ra Pharmaceuticals' Earnings History.

Ra Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, March 5th 2020. View Earnings Estimates for Ra Pharmaceuticals.

11 brokers have issued 1-year price targets for Ra Pharmaceuticals' shares. Their forecasts range from $42.00 to $49.00. On average, they expect Ra Pharmaceuticals' share price to reach $47.50 in the next twelve months. This suggests a possible upside of 1.8% from the stock's current price. View Analyst Price Targets for Ra Pharmaceuticals.

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ra Pharmaceuticals in the last year. There are currently 11 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Ra Pharmaceuticals.

Press coverage about RARX stock has been trending very negative this week, according to InfoTrie. The research group ranks the sentiment of news coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Ra Pharmaceuticals earned a news impact score of -3.0 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the company's share price in the next few days. View News Stories for Ra Pharmaceuticals.

Ra Pharmaceuticals saw a increase in short interest in January. As of January 31st, there was short interest totalling 7,960,000 shares, an increase of 45.0% from the January 15th total of 5,490,000 shares. Based on an average trading volume of 762,900 shares, the short-interest ratio is currently 10.4 days. Currently, 20.5% of the shares of the stock are sold short. View Ra Pharmaceuticals' Current Options Chain.

Some companies that are related to Ra Pharmaceuticals include Ionis Pharmaceuticals (IONS), Jazz Pharmaceuticals (JAZZ), Perrigo (PRGO), Dr.Reddy's Laboratories (RDY), ACADIA Pharmaceuticals (ACAD), Reata Pharmaceuticals (RETA), The Medicines (MDCO), Ascendis Pharma A/S (ASND), Horizon Therapeutics (HZNP), Amarin (AMRN), United Therapeutics (UTHR), BridgeBio Pharma (BBIO), Evotec (EVTCY), Global Blood Therapeutics (GBT) and Arrowhead Pharmaceuticals (ARWR).

Based on aggregate information from My MarketBeat watchlists, some companies that other Ra Pharmaceuticals investors own include Corbus Pharmaceuticals (CRBP), Amarin (AMRN), Viking Therapeutics (VKTX), Advanced Micro Devices (AMD), Fate Therapeutics (FATE), Galmed Pharmaceuticals (GLMD), Immunomedics (IMMU), Novavax (NVAX), Rigel Pharmaceuticals (RIGL) and Verastem (VSTM).

(RARX) raised $75 million in an initial public offering (IPO) on Wednesday, October 26th 2016. The company issued 5,800,000 shares at $12.00-$14.00 per share. Credit Suisse, Jefferies and BMO Capital Markets acted as the underwriters for the IPO and SunTrust Robinson Humphrey was co-manager.

Ra Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional investors include CNH Partners LLC (4.04%), Magnetar Financial LLC (3.90%), Citigroup Inc. (3.70%), State Street Corp (3.47%), Farallon Capital Management LLC (2.52%) and ARP Americas LP (2.13%). Company insiders that own Ra Pharmaceuticals stock include Alonso Ricardo, Enterprise Associates 13 L New, Ra Capital Healthcare Fund Lp, Rajeev M Shah, Ramin Farzaneh-Far and Simon Read. View Institutional Ownership Trends for Ra Pharmaceuticals.

RARX stock was sold by a variety of institutional investors in the last quarter, including Candriam Luxembourg S.C.A., Eagle Asset Management Inc., UBS Asset Management Americas Inc., UBS Group AG, SG Americas Securities LLC, Rafferty Asset Management LLC, Bank of New York Mellon Corp and State Street Corp. Company insiders that have sold Ra Pharmaceuticals company stock in the last year include Alonso Ricardo, Ramin Farzaneh-Far and Simon Read. View Insider Buying and Selling for Ra Pharmaceuticals.

RARX stock was bought by a variety of institutional investors in the last quarter, including CNH Partners LLC, Magnetar Financial LLC, Citigroup Inc., Farallon Capital Management LLC, ARP Americas LP, Gabelli Funds LLC, Renaissance Technologies LLC and Credit Suisse AG. Company insiders that have bought Ra Pharmaceuticals stock in the last two years include Enterprise Associates 13 L New, Ra Capital Healthcare Fund Lp and Rajeev M Shah. View Insider Buying and Selling for Ra Pharmaceuticals.

Shares of RARX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of RARX stock can currently be purchased for approximately $46.68.

Ra Pharmaceuticals has a market capitalization of $2.20 billion and generates $2.50 million in revenue each year. The company earns $-64,940,000.00 in net income (profit) each year or ($2.06) on an earnings per share basis. Ra Pharmaceuticals employs 72 workers across the globe.View Additional Information About Ra Pharmaceuticals.

The official website for Ra Pharmaceuticals is http://www.rapharma.com/.

Ra Pharmaceuticals' mailing address is 87 CAMBRIDGE PARK DRIVE, CAMBRIDGE MA, 02140. The company can be reached via phone at 617-401-4060 or via email at [email protected]